Galmed Pharmaceuticals (GLMD) Common Equity (2013 - 2025)

Galmed Pharmaceuticals' Common Equity history runs 13 years deep, the most recent figure standing at $15.8 million for Q4 2025.

• In Q4 2025, Common Equity fell 3.34% year-over-year to $15.8 million; the TTM figure through Dec 2025 stood at $15.8 million (down 3.34% YoY), while the FY2025 annual figure was $15.8 million, down 3.34% from the prior year.
• Common Equity was $15.8 million for Q4 2025 at Galmed Pharmaceuticals, down from $19.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $53.0 million in Q1 2021 to a low of -$4.1 million in Q1 2023.
• Historically, Common Equity has averaged $20.4 million across 5 years, with a median of $16.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 116.63% in 2023, then jumped 414.89% in 2024.
• A 5-year view of Common Equity shows it stood at $30.5 million in 2021, then slumped by 55.99% to $13.4 million in 2022, then gained by 3.4% to $13.9 million in 2023, then increased by 17.64% to $16.3 million in 2024, then slipped by 3.34% to $15.8 million in 2025.
• The last three Common Equity figures came in at $15.8 million (Q4 2025), $19.1 million (Q3 2025), and $20.5 million (Q2 2025), per Business Quant data.